UK drugmaker GSK under fresh pressure to sell consumer arm

Hedge fund Bluebell also demands replacement of GlaxoSmithKline chairman Sir Jonathan Symonds

The British drugmaker GlaxoSmithKline has come under fresh pressure to sell off its consumer arm and carry out a change of leadership, with a hedge fund demanding the appointment of a new chairman.

Bluebell Capital Partners, an activist London-based hedge fund that has taken a small stake in GSK, has written to the company to demand that Sir Jonathan Symonds be replaced as chairman.

Bluebell recently joined the New York hedge fund Elliott Management, an activist investor that acquired a substantial stake in GSK in May, in demanding that the drugmaker’s chief executive, Emma Walmsley, reapply for her job, before a planned separation of the consumer arm from the pharmaceuticals and vaccines business next summer. The company continues to insist she will lead the latter division after the split.

Symonds held a virtual meeting with GSK’s top 50 investors last week at which the Elliott managing partner Gordon Singer reportedly questioned Walmsley’s leadership and asked why the drugmaker’s share price had fallen below pre-Covid levels.

Bluebell began making similar demands last month. It has taken a stake worth €10m (£8.49m), or 0.01% of GSK.

GSK shares rose as much as 4.8% at one point on Tuesday after a report that private equity firms were circling its consumer arm, but they fell back to close only 1.2% up.

In recent years the drugmaker’s shares have fallen as it has lagged rivals, in particular AstraZeneca, in rebuilding its drug portfolio after the expiration of patents. AZ’s market value has risen to almost twice that of GSK, which is worth about £70bn.

GSK has come under pressure from the two hedge funds to explore a sale of the consumer business, with a value analysts have estimated at about £45bn. However, GSK is pushing ahead with a demerger and insists that this is what most investors want.

Bloomberg reported that private equity firms Advent International, Blackstone, Carlyle Group, CVC Capital Partners and KKR were among those running the rule over the consumer business. It is understood, however, that GSK is not in discussions to sell off the unit.

GSK said it was “far advanced” with its plan for a demerger, adding: “As we have said, the GSK board will fulfil its fiduciary duties to evaluate any alternative options for Consumer Healthcare which may arise that maximise value for all shareholders.”

Bluebell’s managing partners Marco Taricco and Giuseppe Bivona, who launched the hedge fund in 2019, upped the pressure on GSK’s board when they wrote to the company again on Monday to demand the replacement of its chairman.

Bluebell claimed that among the leading shareholders “there remains a broad scepticism of the current leadership, well beyond what has been voiced publicly by selected shareholders”.

Sign up to the daily Business Today email or follow Guardian Business on Twitter at @BusinessDesk

Bluebell wrote: “The separation of Consumer Healthcare should represent a new beginning for New GSK … this includes the appointment not only of a new chief executive but also of a new chairman.”

A GSK spokesperson said: “We completely reject the content and claims made in this letter, which are not representative of the discussion at the meeting or the majority of our shareholders’ views. We are disappointed that Bluebell have deliberately sought to misrepresent the meeting and to distort what was said in order to advance their own narrow agenda.”

They added: “We remain absolutely focused on tackling the root causes of previous historical underperformance and delivering improved and sustained value for all shareholders … The board is confident that we have the right strategy and the right team to deliver a step-change in growth and performance.”

Contributor

Julia Kollewe

The GuardianTramp

Related Content

Article image
GSK drugmaker sets ambitious sales target before shake-up
Firm aims to boost pharmaceutical and vaccine business by 5% annually for five years

Julia Kollewe

23, Jun, 2021 @4:21 PM

Article image
GlaxoSmithKline to sell UK Horlicks brand and scrap factory plans
Company will close Slough plant where malt drink is made and axe proposed Cumbria factory with loss of about 320 jobs

Nick Fletcher

19, Jul, 2017 @2:51 PM

Article image
GSK chief Andrew Witty to leave drugmaker
Chief executive, whose total pay package rose to £6.66m last year, fended off calls last month for break up of multinational

Julia Kollewe

17, Mar, 2016 @9:35 AM

Article image
GlaxoSmithKline set to build drug testing plant in Europe
Drug giant calls for clarity on Brexit and minimum two-year transition period to avoid disruption to medical supplies

Nick Fletcher

25, Oct, 2017 @4:26 PM

Article image
Will Theresa May defend workers' rights? Don't hold your breath | Nils Pratley
The prime minister has been slippery about getting workers on boards – and looks likely to do little about the gig economy

Nils Pratley

16, May, 2017 @11:46 AM

Article image
Even Trump's Twitter binges aren't enough to make it worth $11bn | Nils Pratley
Twitter chief says he is proud daily usage is rising, but revenues just fell and profits are nowhere to be seen

Nils Pratley

27, Apr, 2017 @6:30 AM

Article image
GSK needs no medicine despite talk of poor performance
GlaxoSmithKline’s new chief inherits a business with healthy profit growth and has no need for drastic remedies

Nils Pratley

08, Feb, 2017 @7:49 PM

Article image
GSK is in good health, so no need for new CEO to start looking for medicine
City types may want Emma Walmsley to sort out pharmaceutical firm’s structure but patience is the order of the day

Nils Pratley

20, Sep, 2016 @6:58 PM

Article image
Melrose’s GKN pledges read like Greg Clark invented them to look bold | Nils Pratley
The takeover firm merely vowed to do things it would have done anyway after the minister’s intervention

Nils Pratley

28, Mar, 2018 @6:12 AM

Article image
GSK plans break-up after £10bn Pfizer deal
Merger of consumer healthcare portfolios to pave way for spin-off of drugs business

Angela Monaghan

19, Dec, 2018 @5:57 PM